Highlights

• Telix swung from a US$2 million net loss in H1 2025 to a US$38 million net profit in H1 2026.

• Total Revenue rose 22% to US$477 million, driven by the precision-medicine imaging business.

• Adjusted EBITDA jumped 146% to US$52 million from US$21 million; gross Margin expanded to 55% from 53%.

• The company generated US$23 million of positive operating cash flow, closing the half with US$252 million of cash.

• Research and Development spend rose to US$124 million from US$82 million as Telix continued investing through the transition to profit.

• Management reaffirmed full-year 2026 revenue guidance of US$950-970 million, with total revenue and other income expected above US$1 billion including a US$40 million Regeneron contribution.

• Brain-cancer imaging agent Pixclara carries an FDA action date of 11 September 2026; kidney-cancer candidate Zircaix is progressing through a Biologics licence resubmission.

Telix Pharmaceuticals has been the ASX's most watched biotech, a radiopharmaceutical company that dared to build a commercial imaging Franchise while most peers still burned cash on trials. Its results for the half-year to 30 June 2026, released on 20 August, marked a genuine milestone: revenue pushed toward the US$1 billion annual run-rate, adjusted Earnings more than doubled, and the company swung from a small loss to a clear statutory profit. For a stock long valued on promise, the emergence of real, growing earnings changes the conversation about what Telix is worth and why.

Latest Developments

It is worth being precise about the earnings jump. Telix did not post a clean percentage rise in earnings per share; rather, it swung from a US$2 million net loss in the first half of 2025 to a US$38 million net profit in the first half of 2026. Because the prior period was a loss, a percentage change on EPS is not cleanly defined. The more meaningful framing is the swing to profitability and a 146 per cent lift in adjusted EBITDA, which together mark the transition the market has been waiting for.

Crucially, Telix kept investing through the transition, lifting research and development spend to US$124 million from US$82 million. That the company can fund a heavy pipeline while turning a profit is central to the bull case, and management reaffirmed full-year 2026 revenue guidance of US$950 million to US$970 million, with total revenue and other income expected above US$1 billion including a US$40 million Regeneron contribution.

What the Numbers Show

Total revenue rose 22 per cent to US$477 million, driven by the precision-medicine imaging business, while adjusted EBITDA jumped 146 per cent to US$52 million from US$21 million. Gross margin expanded to 55 per cent from 53 per cent, and the company generated US$23 million of positive operating cash flow, closing the half with US$252 million of cash.

What Could Drive the Stock Next

The pipeline offers a series of near-term catalysts. Telix's brain-cancer imaging agent Pixclara carries an FDA action date of 11 September 2026, and the kidney-cancer candidate Zircaix is progressing through a biologics licence resubmission.

Beyond regulatory events, sustained growth in the core imaging franchise and evidence that new products can layer on top of it would reinforce the shift from a single-product story to a diversified radiopharmaceutical platform, the outcome that would most justify a re-rating. Positive operating cash flow, achieved while revenue still compounds at a double-digit pace, gives management the flexibility to keep funding that expansion internally rather than returning repeatedly to the market.

Key Risks to Watch

Regulatory outcomes are binary and consequential. A delay or rejection at the FDA would remove a catalyst the market is already anticipating and could weigh heavily on a stock priced for pipeline success.

Telix also faces intensifying competition in radiopharmaceuticals from far larger players, and its heavy R&D spend means profitability, though newly achieved, is not guaranteed to be smooth. Reimbursement dynamics, Manufacturing complexity and the concentration of revenue in imaging all remain live risks as the company scales.

Investor Takeaway

Telix's first-half result is a landmark: a swing to statutory profit, sharply higher EBITDA and a Business approaching a billion-dollar revenue run-rate while still investing heavily in its pipeline. The earnings are real, but the valuation still leans on future approvals and continued commercial momentum. The FDA decisions due in the second half will test whether this is the start of a durable new earnings phase or an elevated plateau ahead of the next proving ground.